When kidney cancer is found early and patients are able to undergo surgery, it’s not entirely understood why certain patients relapse and succumb to the disease whilst others do not.

The initial RECUR study occurred between 2006 and 2011 and evaluated 1265 patients. It made huge strides and unearthed some important insights into why these relapses happen on a genetic level, but more work is necessary to understanding this disease and fundamental to improving outcomes across the board.

Marsden-RECUR is one of the biggest studies ever conducted into the genetics of kidney cancers, further investigating the genetics of those 1265 patients. Our funds are being used to support the initial study set up, sample processing, and DNA extraction for a proportion of the tissue samples.

You can find out more about the project via the link below.